Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Spectroscopy can help reduce breast MRI false positives, which tend to increase at various stages of the menstrual cycle, according to researchers at Memorial Sloan-Kettering Cancer Center.
Researchers led by Dr. Lia Bartella performed prospective MRS scans on 27 high-risk subjects undergoing screening breast MRI. Eight were in different stages of their menstrual cycle. The investigators defined a positive MRS as having a choline peak greater than or equal to 2.
The protocol was tested in healthy breast tissue contralateral to the diseased breast. Researchers found that choline did not vary in any of the women and ruled out false positives regardless of a subject's menstrual cycle stage. The result is confidence in true-positive and true-negative findings when they perform MRS in the breast, Bartella said at the 2005 RSNA meeting.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.